This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Bagnyukova T , Serebriiskii IG , Zhou Y , Hopper-Borge EA , Golemis EA , Astsaturov I
Chemotherapy and signaling: How can targeted therapies supercharge cytotoxic agents?
Cancer Biol Ther. 2010 Nov 2;10(9) :839-853
PMID: 20935499 URL: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=20935499
AbstractIn recent years, oncologists have begun to conclude that chemotherapy has reached a plateau of efficacy as a primary treatment modality, even if toxicity can be effectively controlled. Emerging specific inhibitors of signaling and metabolic pathways (i.e., targeted agents) contrast with traditional chemotherapy drugs in that the latter primarily interfere with the DNA biosynthesis and the cell replication machinery. In an attempt to improve on the efficacy, combination of targeted drugs with conventional chemotherapeutics has become a routine way of testing multiple new agents in early phase clinical trials. This review discusses the recent advances including integrative systematic biology and RNAi approaches to counteract the chemotherapy resistance and to buttress the selectivity, efficacy and personalization of anti-cancer drug therapy.
NotesJournal article Cancer biology & therapy Cancer Biol Ther. 2010 Nov 2;10(9).